You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. sHLA Protein Chip

    SBC: GENOMICS USA, INC.            Topic: NIAID

    Abstract: “sHLA Protein Chip” The class I [A, B, C] and class II HLA proteins [DRB1, DQ, DP] comprise the heart of the inducible human immune system. For organ, marrow and stem cell transplantation, the development of serum-born antibodies against one or more of those many HLA proteins comprises the best and earliest test for transplant rejection. Because of the enormous medical importance of ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Topic 346: Targeted Radionuclide Therapy of Neuroendocrine Tumors Using 212Pb-octreotate Analogs

    SBC: RADIOMEDIX, INC.            Topic: NCI

    A peptide receptor radionuclide therapy (PRRT) using [177Lu]/[90Y]-labeled somatostatin analogs has been proven to induce objective response in 30-45% of patients with advanced/progressive neuroendocrine tumors (NETs). The complete response to beta-emitter PRRT is rare. This is due to the fact that NETs are diagnosed at late stage of disease; the NETs patients with remissions could develop resista ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Improving Patient Outcomes through Tracking and Displaying the Disinfection Status of Equipment and Area

    SBC: XENEX DISINFECTION SERVICES INC.            Topic: 600

    Inhealthcare associated infectionsHAIswere reported in the United StatesDaily and terminal disinfection of hospital areas such as patient rooms are critically important to help prevent HAI and involve extensive disinfection of the room before a new patient is admitted to the roomAdditionallyportable medical equipmentPMEhas been implicated in outbreaks of HAIs and the importance of systematic disin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Zinc(II) Sensitive MRI Contrast Agents as Diagnostic Sensors for Tracking Insulin Secretion

    SBC: VITALQUAN LIMITED LIABILITY COMPANY            Topic: NIDDK

    ABSTRACT SignificanceDiabetes mellitus typeT Dand particularly typeT Dandgtof casesare becoming an increasing burden on socioeconomic resources with vastly increasing patient numbers all over the worldInsulin dependent treatment regimen such as regular insulin injections are well established for both T D and T D but have been associated with a negative impact on the quality of life of patients wit ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: NIEHS

    Summary Enhanced Recovery of Pharmaceutical Solvent driven by EPA InitiativeThe United States Environmental Protection AgencyEPAis establishing new safeguards for hazardous secondary materials with objectives to promote the economicenvironmentaland public health benefits of recycling wasteswith an emphasis on several industrial sectorsincluding the pharmaceutical industryOn averagepharmaceutical m ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A smartphone-based point-of-care test for detection of Chlamydia trachomatis

    SBC: LUMINOSTICS INC            Topic: NIAID

    ABSTRACT The ultimate goal of this project is CLIP CTan FDA cleared and CE marked smartphone based testminfor Chlamydia trachomatisCTinfections in women in over the counterOTCand point of carePOCsettingsCT is the most common bacterial cause of sexually transmitted infectionswith almostmillion new cases in the US each yearUntreated womenmostly in theage groupare at high risk of serious sequelae inc ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government